[Monoclonal antibodies in cardiovascular diseases and metabolic disorders today].
Place des anticorps thérapeutiques dans les maladies cardiovasculaires et métaboliques aujourd’hui.
Journal
Medecine sciences : M/S
ISSN: 1958-5381
Titre abrégé: Med Sci (Paris)
Pays: France
ID NLM: 8710980
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
entrez:
7
1
2020
pubmed:
7
1
2020
medline:
23
6
2020
Statut:
ppublish
Résumé
The use of monoclonal antibodies in cardiovascular diseases and metabolic disorders is still in its infancy. Recent development of anti-PCSK9 monoclonal antibodies for the treatment of dyslipidemia and of patients in secondary prevention is a breakthrough in the field. Anti- PCSK9 antibodies significantly improved LDL cholesterol reduction in patients with familial hypercholesterolemia. These antibodies have also demonstrated a significant reduction of clinical events in patients with previously established atherosclerotic disease such as myocardial infarction, ischemia stroke or peripheral artery disease. Other targets are under investigation such as inflammatory cells and cytokines to reduce atherosclerosis or myocardial lesions following myocardial infarction. Place des anticorps thérapeutiques dans les maladies cardiovasculaires et métaboliques aujourd’hui. La place des anticorps thérapeutiques dans les maladies cardiovasculaires et métaboliques est encore modeste en 2019 en comparaison à leur incroyable développement dans d’autres champs pathologiques. Cependant, l’arrivée récente des anticorps anti-PCSK9 (proprotein convertase subtilisin/kexin de type 9) dans l’arsenal thérapeutique va probablement changer la donne. Ces anticorps permettent non seulement d’améliorer la prise en charge des patients porteurs d’hypercholestérolémie familiale mais également de réduire le risque de complications cliniques de l’athérosclérose en prévention secondaire après un infarctus du myocarde, une artériopathie périphérique ou un accident vasculaire cérébral ischémique. D’autres stratégies thérapeutiques sont en cours d’investigation, ciblant notamment des cellules et cytokines impliquées dans les réponses immuno-inflammatoires avec pour objectif de prévenir les complications de l’athérosclérose ou les lésions du myocarde au décours d’un infarctus.
Autres résumés
Type: Publisher
(fre)
Place des anticorps thérapeutiques dans les maladies cardiovasculaires et métaboliques aujourd’hui.
Identifiants
pubmed: 31903910
doi: 10.1051/medsci/2019224
pii: msc190034
doi:
Substances chimiques
Antibodies, Monoclonal
0
PCSK9 protein, human
EC 3.4.21.-
Proprotein Convertase 9
EC 3.4.21.-
Types de publication
Journal Article
Review
Langues
fre
Sous-ensembles de citation
IM
Pagination
1014-1016Informations de copyright
© 2019 médecine/sciences – Inserm.
Références
Investigators EPIC. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994 ; 330: 956–961.
Smith TW, Haber E, Yeatman L, et al. Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies. N Engl J Med 1976 ; 294: 797–800.
Testa L, Van Gaal WJ, Bhindi R, et al. Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients. J Thorac Cardiovasc Surg 2008 ; 136: 884–893.
Baran KW, Nguyen M, McKendall GR, et al. Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study. Circulation 2001 ; 104: 2778–2783.
Rusnak JM, Kopecky SL, Clements IP, et al. An anti-CD11/CD18 monoclonal antibody in patients with acute myocardial infarction having percutaneous transluminal coronary angioplasty (the FESTIVAL study). Am J Cardiol 2001 ; 88: 482–487.
Stähli BE, Gebhard C, Duchatelle V, et al. Effects of the P-selectin antagonist Inclacumab on myocardial damage after percutaneous coronary intervention according to timing of infusion: Insights from the SELECT-ACS trial. J Am Heart Assoc 2016; 5.
Carroll MB, Haller C, Smith C. Short-term application of tocilizumab during myocardial infarction (STAT-MI). Rheumatol Int 2018 ; 38: 59–66.
Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with Canakinumab for atherosclerotic disease. N Engl J Med 2017 ; 377: 1119–1131.
Ridker PM, MacFadyen JG, Thuren T, et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 2017 ; 390: 1833–1842.
Abifadel M, Varret M, Rabès JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003 ; 34: 1546.
Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017 ; 376: 17: 1322.
Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018 ; 379: 2097–2107.
Ridker PM, Revkin J, Amarenco P, et al. Cardiovascular efficacy and safety of Bococizumab in high-risk patients. N Engl J Med 2017 ; 376: 1527–1539.
Stoekenbroek RM, Kallend D, Wijngaard PL, et al. Inclisiran for the treatment of cardiovascular disease: the ORION clinical development program. Future Cardiol 2018 ; 14: 433–442.
Daifotis AG, Koenig S, Chatenoud L, et al. Anti-CD3 clinical trials in type 1 diabetes mellitus. Clin Immunol 2013 ; 149: 268–278.